 BERKELEY, Calif. and VANCOUVER, British Columbia, April 15, 2021 GLOBE NEWSWIRE -- BriaCell Therapeutics Corp. Nasdaq: BCTX, BCTXW TSX-V:BCT BriaCell or the Company, a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces that it has recently expanded its investor and media outreach platform in order to enhance communication with investors and increase investor awareness of and interest in the Company, its product candidates, and its clinical programs. The comprehensive program is expected to enhance BriaCells dialogue with institutional and retail investors, industry analysts, and the investing public. The following IR and PR groups are currently engaged by the Company. It is important to disclose that BriaCell is unrelated and unaffiliated with each of the following entities, but the following firms and their clients may have an interest, directly or indirectly, in the securities of BriaCell. 